Drawing for ZYAMTIN

USPTO serial 99175897

ZYAMTIN

Reviewed by CopyMark Law Group

Reg. 8067143Status 700Registered
Filing date
Status date
Registration date
Dec 16, 2025
Examiner
WOODS, TRAVIS R
Law office
FILE REPOSITORY (FRANCONIA)

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with ZYAMTIN?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

JULIANNE ABELMAN

JULIANNE ABELMAN ABELMAN LAW PLLC16 Sutton PlSuite 5BNew York, NY 10022

Goods and services

ClassDescriptionStatusFirst use
005Biological preparations for medical use in medical and clinical gene therapy and cell therapy; clinical medical reagents for use in gene therapy, gene diagnosis, and gene testing; pharmaceutical preparations, namely, vaccines for use in gene therapy; pharmaceutical preparations for the treatment of Dravet's disease, Alzheimer's disease, ALS, Huntington's disease, Fragile X syndrome, Parkinson's disease, A1AT deficiency, epilepsy, temporal lobe epilepsy, focal cortical dysplasia, Fabry disease, multiple system atrophy, spinocerebellar ataxia and dyslipidemia; gene therapy and prophylaxis products, namely, gene-based biological preparations and medical reagents for use in gene regulation and gene modulation for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, cancer, inflammatory and auto-immune diseases, vascular disorders, and single gene disordersACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Dec 16, 2025NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Dec 16, 2025R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Oct 28, 2025NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Oct 28, 2025PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Oct 22, 2025NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Sep 24, 2025CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Sep 24, 2025DOCKASSIGNED TO EXAMINER—
Jun 20, 2025TAEATEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED—
Jun 20, 2025PARITEAS VOLUNTARY AMENDMENT RECEIVED—
May 8, 2025MAFRAPPLICATION FILING RECEIPT MAILED—
May 8, 2025NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
May 8, 2025NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance